The first cases of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), were reported in Zambia in March 2020 (1). During the first wave of infections, confirmed cases rapidly increased during July and peaked in August 2020 (Appendix, https://wwwnc.cdc.gov/EID/article/27/8/21-0502-App1.pdf). Zambia initially focused on screening travelers at points-of-entry and tracing contacts of persons with laboratory-confirmed cases. In April 2020, the Zambia Ministry of Health began SARS-CoV-2 surveillance among hospital inpatients and outpatients to identify cases of local transmission (1,2). It was believed that testing in health facilities would be more efficient at identifying cases than testing in the general population, which was particularly noteworthy given the severe shortage of SARS-CoV-2 tests in Africa early in the pandemic (3,4). A household prevalence survey conducted in 6 districts in Zambia in July 2020 found a community SARS-CoV-2 prevalence of 7.6% by using real-time PCR (rPCR) (5). To determine if facility testing was an effective case-finding strategy during a period of high community transmission, we compared SARS-CoV-2 prevalence among outpatients, overall and stratified by reasons for visiting the facility, with prevalence among community members in the same districts (5).

The Study
During July 2–31, 2020, we administered a cross-sectional prevalence survey of patients attending 20 outpatient clinics, including hospitals and health centers, in 6 districts in Zambia (Appendix). The number of facilities we selected in each district was proportional to the number of facilities in the other districts (Appendix). We recruited participants from outpatient departments regardless of their reason for visiting the facilities. Study teams were instructed to recruit ≥50 participants per facility and to attempt to show no preference in selection. We obtained consent or assent (for minors) before beginning study procedures. Participants completed an interviewer-administered questionnaire that included demographics, medical history, SARS-CoV-2 exposures, history of recent illness, and reason for visiting the facility. Concurrently, we conducted a cluster-sampled household prevalence survey in the same 6 districts (5). These surveys provided an opportunity to directly compare outpatient and community SARS-CoV-2 prevalence estimates. The study was approved by the Zambia National Health Research Authority and the University of Zambia Biomedical Research Ethics Committee. The activity was reviewed by the US Centers for Disease Control and Prevention (CDC) and conducted consistent with applicable US federal law and CDC policy.
We tested nasopharyngeal specimens for SARS-CoV-2 RNA by using rPCR and plasma specimens for SARS-CoV-2 antibodies by using ELISA. We extracted RNA for rPCR using the QIAGEN Viral Mini procedure (https://www.qiagen.com). We used the Maccura SARS-CoV-2 Fluorescent PCR kit (https://www.maccura.com) on the QuantStudio 3 platform (ThermoFisher, https://www.thermofisher.com) as the primary rPCR diagnostic (6) and used the CDC assay method to confirm positive and indeterminant results (7). We performed the Euroimmun ELISA (PerkinElmer, https://www.perkinelmer.com) to test for spike protein IgG in single replicate (8). Participants could take part in any or all of the survey, rPCR testing, or serologic testing options based on personal preference.

We calculated SARS-CoV-2 prevalence as the number of positive results divided by the total number of tests conducted. Estimates were calculated separately for rPCR and ELISA results. We adjusted variance and 95% CIs for clustering by facility and seroprevalence for imperfect assay test characteristics (sensitivity 64.2%; specificity 100%; L. Steinhardt, pers. comm., email, 2021 Apr 2) using the Rogan-Gladen method (Appendix). To assess various factors associated with SARS-CoV-2 prevalence among outpatients, we used bivariate Poisson regression models to calculate prevalence ratios (PRs) and 95% CIs, with a random effects term for facility.

Of 1,975 persons representing ≈57,000 outpatients from the 20 facilities that we approached in July 2020 about participating (District Health Information System version 2; https://dhis2.org), 1,952 (98.8%) completed the questionnaire and 1,908 (97.7%) submitted either nasopharyngeal (1,490; 76.3%) or blood (1,657; 84.3%) specimens or both (Appendix). Of the 1,952 total participants, the number per district ranged from 160 (8.2%) in Nakonde District to 639 (32.8%) in Lusaka District; the median number of participants per facility was 93 (interquartile range 78–107; Table 1, https://wwwnc.cdc.gov/EID/article/27/8/21-0502-App1.pdf). Median participant age was 32 years (interquartile range 24–43 years); 60.5% were female. Overall, 34.1% of participants reported having a coexisting medical condition. Fever or respiratory complaints accounted for 28.2% of reasons for visiting the facility; 2.3% of participants were specifically seeking COVID-19 testing.

SARS-CoV-2 rPCR-measured prevalence was 13.4% (95% CI 8.3%–18.5%; Table 1); SARS-CoV-2 ELISA-measured prevalence was 8.2% (95% CI 5.1%–11.4%). Compared with community members, outpatients overall had higher rPCR-measured prevalence (PR 1.8, 95% CI 1.1–2.9; Table 2) as did those seeking COVID-19 testing (PR 3.6, 95% CI 2.2–5.9) or those without a stated reason for the visit (PR 2.0, 95% CI 1.2–3.3). Although only 2.2% of participants reported contact with confirmed COVID-19 case-patients, rPCR-measured prevalence was higher among outpatients specifically seeking COVID-19 testing compared with outpatients attending facilities for another reason (PR 2.2, 95% CI 1.4–3.3). In addition, outpatients had higher ELISA-measured prevalence than community members (PR 2.5, 95% CI 1.4–4.5) (Appendix). Among outpatients with SARS-CoV-2 infection, 45.7% did not report experiencing any symptoms associated with SARS-CoV-2.

Conclusions
Outpatients had higher SARS-CoV-2 prevalence than did community members in Zambia. Given the high SARS-CoV-2 prevalence and proportion of asymptomatic infections among outpatients, without instituting protective measures facilities might become transmission foci. Ameliorating risk requires instituting robust prevention and control strategies including universal masking in facilities (9,10). Furthermore, persons seeking testing at facilities should be quickly identified and isolated, because they might be at particularly high risk for having the virus.

One limitation of our study is that underlying condition and exposure history are subject to self-report

![Table 2. Severe acute respiratory syndrome coronavirus 2 prevalence measured by PCR, prevalence ratios, and absolute prevalence differences between community members and outpatient participants, stratified by reason for attending the health facility, Zambia, July 2020](https://wwwnc.cdc.gov/EID/article/27/8/21-0502-App1.pdf)

<table>
<thead>
<tr>
<th>Population</th>
<th>Prevalence, % (95% CI)</th>
<th>Prevalence ratio (95% CI)</th>
<th>Absolute difference, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community members, † n = 2,990</td>
<td>7.6 (4.7–10.8)</td>
<td>Referent</td>
<td>Referent</td>
</tr>
<tr>
<td>Outpatients, n = 1,490</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>13.4 (8.3–18.5)</td>
<td>1.8 (1.1–2.9)</td>
<td>5.7 (0.3–11.2)</td>
</tr>
<tr>
<td>Fever or respiratory complaint</td>
<td>12.9 (6.6–19.2)</td>
<td>1.7 (0.9–3.0)</td>
<td>5.3 (1.2–11.7)</td>
</tr>
<tr>
<td>COVID-19 testing</td>
<td>27.5 (17.7–37.3)</td>
<td>3.6 (2.2–5.9)</td>
<td>19.9 (10.5–29.3)</td>
</tr>
<tr>
<td>Other acute medical complaints</td>
<td>10.7 (5.6–15.7)</td>
<td>1.4 (0.8–2.5)</td>
<td>3.0 (0.2–4.2)</td>
</tr>
<tr>
<td>Routine health visit</td>
<td>12.5 (4.6–20.3)</td>
<td>1.6 (0.8–3.2)</td>
<td>4.8 (0.2–9.9)</td>
</tr>
<tr>
<td>Not specified</td>
<td>15.5 (9.8–21.2)</td>
<td>2.0 (1.2–3.3)</td>
<td>7.9 (2.0–13.8)</td>
</tr>
</tbody>
</table>

*COVID-19, coronavirus disease.
† Estimates derived from a cluster-sampled household prevalence survey conducted among community members in the same 6 districts (Kabwe, Livingstone, Lusaka, Nakonde, Ndola, and Solwezi) as in the outpatient prevalence study.
and recall biases. The districts and facilities were not randomly selected and, despite our intentions to remain unbiased, may not have been representative of the population. The small sample size may have affected our ability to detect differences in factors associated with SARS-CoV-2 prevalence. The higher ELISA-measured prevalence among outpatients than community members could signal noncomparability between these 2 populations or that being an outpatient is a possible marker for other behaviors that increase SARS-CoV-2 infection risk. We assumed exact sensitivity and specificity values for the serology assay, but emerging evidence on serologic cross-reactivity (11–13) and antibody decay (14) might affect these values. However, given the timing of our study early in the outbreak, antibody decay was unlikely to substantially affect sensitivity (J. Perez-Saez, unpub. data, https://doi.org/10.1016/j.ijid.2020.10.104 10.1016/S2214-109X(21)00053-X)

Countries with limited testing capacity need efficient strategies to identify persons with SARS-CoV-2 infections to interrupt transmission. In Zambia, when measured by rPCR, outpatients had 80% higher SARS-CoV-2 prevalence than persons in the surrounding community. Testing all outpatients regardless of their reasons for visiting the facility during periods of community transmission might help identify otherwise undetected SARS-CoV-2 infections. Compared with community-based SARS-CoV-2 testing, outpatient testing, which is often more convenient, might identify cases more effectively. Therefore, testing at facilities during periods of high community transmission might be an effective strategy to identify persons with SARS-CoV-2 infection, especially when testing capacity is limited.

This work has been supported by the President’s Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention and its emergency response to the COVID-19 pandemic.

About the Author
Dr. Hines is the surveillance advisor in the US Centers for Disease Control and Prevention and its emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention and its emergency response to the COVID-19 pandemic.

References

Address for correspondence: Jonas Z. Hines, CDC–Zambia Office, PO Box 320065, 351 Independence Way, Woodlands, Lusaka, Zambia; email: jhines1@cdc.gov
SARS-CoV-2 Prevalence among Outpatients during Community Transmission, Zambia, July 2020

Appendix

Supplemental Methods

We calculated prevalence estimates using SURVEY procedures in SAS version 9.4 (SAS Institute, https://www.sas.com). The raw seroprevalence estimate was 5.3% (95% CI: 3.3%–7.3%). We adjusted seroprevalence and 95% CI estimates from SAS for imperfect assay characteristics using an R (R-project, https://www.r-project.org) function for the Rogen-Gladen estimator equation (1,2):

\[
\text{Adjusted prevalence} = \frac{\text{Crude prevalence} + (\text{Specificity} - 1)}{\text{Specificity} + (\text{Specificity} - 1)}
\]

# Function to adjust prevalence estimate according to Rogen-Gladen equation
# Specify the dataset, sensitivity, and specificity
# 'crude' is a data frame with 4 columns: variable name, crude prevalence,
# lower confidence limit, upper confidence limit
# 'sensitivity' and 'specificity' are objects with values for the assay's
# sensitivity and specificity
Adjust <- function(crude, sensitivity, specificity) {
  adjusted <- ((crude[1:nrow(crude), 2:4]/100 + specificity - 1)/(sensitivity + specificity - 1)*100
  adjusted <- cbind(crude[,1], adjusted)
  print(adjusted)
}

The Euroimmun SARS-CoV-2 IgG assay is a semiquantitative ELISA for detecting SARS-CoV-2 spike protein subunit 1 IgG in human serum or plasma. For the Euroimmun assay, a U.S. Food and Drug Administration validation study reported a sensitivity of 90% and a
specificity of 100% (3). However, the real world performance of this assay might be lower (4,5). An in-country validation study of Euroimmun was not performed in Zambia. As an alternative, we used sensitivity (64.2%) and specificity (100%) estimates for Euroimmun spike IgG assay from a unpublished study from Nigeria (Laura Steinhardt, personal communication) as the most applicable data for adjusting the seroprevalence estimate in our study. The unpublished study from Nigeria was conducted at the Center for Human Virology and Genomics at the Nigeria Institute of Medical Research (NIMR) in Lagos. The negative panel consisted of 50 HIV-positive samples and 49 hepatitis B surface antigen–positive samples collected and archived before October 2019. The positive panel consisted of 96 convalescent plasma specimens collected from outpatients ≥18 years testing PCR positive for SARS-CoV-2 at NIMR. Although data are emerging on factors that may impact serologic assay sensitivity and specificity by geographic locations or by the length of time following infection (6–10; J. Perez-Saez, unpub. data, https://doi.org/10.1101/2021.03.16.21253710), for the purpose of this analysis we assumed the exact values and applied the transformation to the upper and lower CI bounds.

References


Appendix Table 1. Distribution and inclusion of health care facilities of sample by district*

<table>
<thead>
<tr>
<th>Category</th>
<th>Kabwe</th>
<th>Livingstone</th>
<th>Lusaka</th>
<th>Nakonde</th>
<th>Ndola</th>
<th>Solwezi</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total health facilities by district</td>
<td>395</td>
<td>266</td>
<td>652</td>
<td>156</td>
<td>330</td>
<td>257</td>
<td>2,056</td>
</tr>
<tr>
<td>No. health facilities in study by district</td>
<td>3</td>
<td>3</td>
<td>6</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>20</td>
</tr>
<tr>
<td>% Health facilities in study from each district</td>
<td>19.2%</td>
<td>12.9%</td>
<td>31.7%</td>
<td>7.6%</td>
<td>16.1%</td>
<td>12.5%</td>
<td>100%</td>
</tr>
</tbody>
</table>

*3 health facilities were COVID-19 treatment centers in Kabwe, Livingstone, and Lusaka

Appendix Table 2. Differences in SARS-CoV-2 prevalence measured by ELISA between community members and outpatient participants, stratified by reason for attending the health facility.

<table>
<thead>
<tr>
<th>Population</th>
<th>Prevalence, % (95% CI)</th>
<th>Prevalence ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Community members† (n = 2,704)</td>
<td>3.2 (1.7–4.8)‡</td>
<td>Referent</td>
</tr>
<tr>
<td>Outpatients (n = 1,490)</td>
<td>Overall 8.2 (5.1–11.4)</td>
<td>2.5 (1.4–4.5)</td>
</tr>
<tr>
<td></td>
<td>Fever or respiratory complaint 9.6 (3.5–14.4)</td>
<td>3.4 (1.8–6.6)</td>
</tr>
<tr>
<td></td>
<td>COVID-19 testing 0.0</td>
<td>Not calculated</td>
</tr>
<tr>
<td></td>
<td>Other acute medical complaints 7.1 (4.6–9.7)</td>
<td>2.3 (1.3–4.0)</td>
</tr>
<tr>
<td></td>
<td>Routine health visit 5.0 (2.0–8.1)</td>
<td>1.7 (0.8–3.6)</td>
</tr>
<tr>
<td></td>
<td>Not specified 7.5 (2.6–12.4)</td>
<td>2.6 (1.2–5.4)</td>
</tr>
</tbody>
</table>

*COVID-19, coronavirus disease
†Estimates derived from a cluster-sampled household prevalence survey conducted among community members in the same 6 districts (Kabwe, Livingstone, Lusaka, Nakonde, Ndola, and Solwezi) as in the outpatient prevalence study (17).
‡Estimate differs from the published estimate of 2.1% (95% CI 1.1%–3.1%) because it has been adjusted for the imperfect test characteristics of the Euroimmun assay using the Rogen-Gladen estimator equation.
Appendix Figure 1. Confirmed SARS-CoV-2 infections by week of laboratory confirmation in six districts (Kabwe, Livingstone, Lusaka, Nakonde, Ndola, and Solwezi) in Zambia, March–December 2020. Outpatients survey data was collected July 2–31, 2020, household survey data was collected July 4–27, 2020.
Appendix Figure 2. District locations for SARS-CoV-2 prevalence study among outpatients in six districts (Kabwe, Livingstone, Lusaka, Nakonde, Ndola, and Solwezi) in Zambia, July 2020.
Appendix Figure 3. SARS-CoV-2 prevalence study flow diagram with sample sizes, response rates, and prevalence estimates in six districts (Kabwe, Livingstone, Lusaka, Nakonde, Ndola, and Solwezi) in Zambia, July 2020.